Genmab — Februar 2015
-
http://www.derivate.bnpparibas.com/zertifikat/details/genmab-mini-long/de000ps2efl4 Cibor 1 mdr eller 3,5%. Har ikke lige tid til at finde svaret lige nu.
-
Genmab kan vidst stadig gå højere: http://www.bloomberg.com/news/articles/2015-02-26/cancer-drug-once-bought-for-7-million-may-now-fetch-18-billion
-
While there are of course differences on the compounds, and on the respective deals that J&J has with PCYC and Genmab, we have still been arguing for a long time that PCYC is a rather good peer to Genmab. A bid on Pharmacyclics would likely impact the Genmab valuation.
-
man kan håbe Novartis løber med PCYC fordi det vil 1) Være godt for Arzerra 2) Gøre Jannsen endnu mere sultne på andre opkøb (læs genmab)
-
Men det gælder selvfølgelig også den anden vej rundt af tager J&J PCYC kan det gøre Novartis desperate
-
Har stadig alle dem jeg altid har haft men har nu ikke gearet mig til skorstenen endnu solsen hvis det er det du tænker på
-
Jeg bruger SAXO ved du godt Helge
-
500 er heller ikke sjovt for Marshall. Vi skal jo ikke være alt for hårde ved dem
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind